

# Breakthrough Therapy (BT) Designation-Global Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/B7A5FF21892MEN.html

Date: May 2018

Pages: 152

Price: US\$ 2,480.00 (Single User License)

ID: B7A5FF21892MEN

### **Abstracts**

### **Report Summary**

Breakthrough Therapy (BT) Designation-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Breakthrough Therapy (BT) Designation industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Breakthrough Therapy (BT) Designation 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Breakthrough Therapy (BT) Designation worldwide, with company and product introduction, position in the Breakthrough Therapy (BT) Designation market

Market status and development trend of Breakthrough Therapy (BT) Designation by types and applications

Cost and profit status of Breakthrough Therapy (BT) Designation, and marketing status Market growth drivers and challenges

The report segments the global Breakthrough Therapy (BT) Designation market as:

Global Breakthrough Therapy (BT) Designation Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America



Europe

China

Japan

**Rest APAC** 

Latin America

Global Breakthrough Therapy (BT) Designation Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Oncology

Infectious Diseases

Rare Diseases

**Autoimmune Diseases** 

**Pulmonary Diseases** 

**Neurological Disorders** 

Others

Global Breakthrough Therapy (BT) Designation Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinic

Research Institute

Laboratories

Global Breakthrough Therapy (BT) Designation Market: Manufacturers Segment Analysis (Company and Product introduction, Breakthrough Therapy (BT) Designation Sales Volume, Revenue, Price and Gross Margin):

Roche

**Abbvie** 

Novartis International AG

Janssen

**BMS** 

Eli Lilly

Gilead

Sanofi

Regeneron



Acadia

Boehringer Ingelheim

Amgen

AstraZeneca

GlaxoSmithKline

Vertex

Alexion

Merck

Jazz Pharmaceuticals

Exelixis

Eisai

Takeda

Pfizer

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



### **Contents**

### CHAPTER 1 OVERVIEW OF BREAKTHROUGH THERAPY (BT) DESIGNATION

- 1.1 Definition of Breakthrough Therapy (BT) Designation in This Report
- 1.2 Commercial Types of Breakthrough Therapy (BT) Designation
  - 1.2.1 Oncology
  - 1.2.2 Infectious Diseases
  - 1.2.3 Rare Diseases
  - 1.2.4 Autoimmune Diseases
  - 1.2.5 Pulmonary Diseases
  - 1.2.6 Neurological Disorders
  - 1.2.7 Others
- 1.3 Downstream Application of Breakthrough Therapy (BT) Designation
  - 1.3.1 Hospital
  - 1.3.2 Clinic
  - 1.3.3 Research Institute
- 1.3.4 Laboratories
- 1.4 Development History of Breakthrough Therapy (BT) Designation
- 1.5 Market Status and Trend of Breakthrough Therapy (BT) Designation 2013-2023
- 1.5.1 Global Breakthrough Therapy (BT) Designation Market Status and Trend 2013-2023
- 1.5.2 Regional Breakthrough Therapy (BT) Designation Market Status and Trend 2013-2023

#### CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Breakthrough Therapy (BT) Designation 2013-2017
- 2.2 Sales Market of Breakthrough Therapy (BT) Designation by Regions
  - 2.2.1 Sales Volume of Breakthrough Therapy (BT) Designation by Regions
  - 2.2.2 Sales Value of Breakthrough Therapy (BT) Designation by Regions
- 2.3 Production Market of Breakthrough Therapy (BT) Designation by Regions
- 2.4 Global Market Forecast of Breakthrough Therapy (BT) Designation 2018-2023
- 2.4.1 Global Market Forecast of Breakthrough Therapy (BT) Designation 2018-2023
- 2.4.2 Market Forecast of Breakthrough Therapy (BT) Designation by Regions 2018-2023

#### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**



- 3.1 Sales Volume of Breakthrough Therapy (BT) Designation by Types
- 3.2 Sales Value of Breakthrough Therapy (BT) Designation by Types
- 3.3 Market Forecast of Breakthrough Therapy (BT) Designation by Types

### CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of Breakthrough Therapy (BT) Designation by Downstream Industry
- 4.2 Global Market Forecast of Breakthrough Therapy (BT) Designation by Downstream Industry

### CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America Breakthrough Therapy (BT) Designation Market Status by Countries
- 5.1.1 North America Breakthrough Therapy (BT) Designation Sales by Countries (2013-2017)
- 5.1.2 North America Breakthrough Therapy (BT) Designation Revenue by Countries (2013-2017)
- 5.1.3 United States Breakthrough Therapy (BT) Designation Market Status (2013-2017)
  - 5.1.4 Canada Breakthrough Therapy (BT) Designation Market Status (2013-2017)
  - 5.1.5 Mexico Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 5.2 North America Breakthrough Therapy (BT) Designation Market Status by Manufacturers
- 5.3 North America Breakthrough Therapy (BT) Designation Market Status by Type (2013-2017)
- 5.3.1 North America Breakthrough Therapy (BT) Designation Sales by Type (2013-2017)
- 5.3.2 North America Breakthrough Therapy (BT) Designation Revenue by Type (2013-2017)
- 5.4 North America Breakthrough Therapy (BT) Designation Market Status by Downstream Industry (2013-2017)

### CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

6.1 Europe Breakthrough Therapy (BT) Designation Market Status by Countries



- 6.1.1 Europe Breakthrough Therapy (BT) Designation Sales by Countries (2013-2017)
- 6.1.2 Europe Breakthrough Therapy (BT) Designation Revenue by Countries (2013-2017)
  - 6.1.3 Germany Breakthrough Therapy (BT) Designation Market Status (2013-2017)
  - 6.1.4 UK Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 6.1.5 France Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 6.1.6 Italy Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 6.1.7 Russia Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 6.1.8 Spain Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 6.1.9 Benelux Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 6.2 Europe Breakthrough Therapy (BT) Designation Market Status by Manufacturers
- 6.3 Europe Breakthrough Therapy (BT) Designation Market Status by Type (2013-2017)
  - 6.3.1 Europe Breakthrough Therapy (BT) Designation Sales by Type (2013-2017)
- 6.3.2 Europe Breakthrough Therapy (BT) Designation Revenue by Type (2013-2017)
- 6.4 Europe Breakthrough Therapy (BT) Designation Market Status by Downstream Industry (2013-2017)

# CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Breakthrough Therapy (BT) Designation Market Status by Countries
- 7.1.1 Asia Pacific Breakthrough Therapy (BT) Designation Sales by Countries (2013-2017)
- 7.1.2 Asia Pacific Breakthrough Therapy (BT) Designation Revenue by Countries (2013-2017)
- 7.1.3 China Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 7.1.4 Japan Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 7.1.5 India Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 7.1.6 Southeast Asia Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 7.1.7 Australia Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 7.2 Asia Pacific Breakthrough Therapy (BT) Designation Market Status by Manufacturers
- 7.3 Asia Pacific Breakthrough Therapy (BT) Designation Market Status by Type (2013-2017)
  - 7.3.1 Asia Pacific Breakthrough Therapy (BT) Designation Sales by Type (2013-2017)
- 7.3.2 Asia Pacific Breakthrough Therapy (BT) Designation Revenue by Type (2013-2017)
- 7.4 Asia Pacific Breakthrough Therapy (BT) Designation Market Status by Downstream



Industry (2013-2017)

# CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Breakthrough Therapy (BT) Designation Market Status by Countries
- 8.1.1 Latin America Breakthrough Therapy (BT) Designation Sales by Countries (2013-2017)
- 8.1.2 Latin America Breakthrough Therapy (BT) Designation Revenue by Countries (2013-2017)
  - 8.1.3 Brazil Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 8.1.4 Argentina Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 8.1.5 Colombia Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 8.2 Latin America Breakthrough Therapy (BT) Designation Market Status by Manufacturers
- 8.3 Latin America Breakthrough Therapy (BT) Designation Market Status by Type (2013-2017)
- 8.3.1 Latin America Breakthrough Therapy (BT) Designation Sales by Type (2013-2017)
- 8.3.2 Latin America Breakthrough Therapy (BT) Designation Revenue by Type (2013-2017)
- 8.4 Latin America Breakthrough Therapy (BT) Designation Market Status by Downstream Industry (2013-2017)

# CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa Breakthrough Therapy (BT) Designation Market Status by Countries
- 9.1.1 Middle East and Africa Breakthrough Therapy (BT) Designation Sales by Countries (2013-2017)
- 9.1.2 Middle East and Africa Breakthrough Therapy (BT) Designation Revenue by Countries (2013-2017)
  - 9.1.3 Middle East Breakthrough Therapy (BT) Designation Market Status (2013-2017)
  - 9.1.4 Africa Breakthrough Therapy (BT) Designation Market Status (2013-2017)
- 9.2 Middle East and Africa Breakthrough Therapy (BT) Designation Market Status by Manufacturers
- 9.3 Middle East and Africa Breakthrough Therapy (BT) Designation Market Status by Type (2013-2017)



- 9.3.1 Middle East and Africa Breakthrough Therapy (BT) Designation Sales by Type (2013-2017)
- 9.3.2 Middle East and Africa Breakthrough Therapy (BT) Designation Revenue by Type (2013-2017)
- 9.4 Middle East and Africa Breakthrough Therapy (BT) Designation Market Status by Downstream Industry (2013-2017)

# CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Breakthrough Therapy (BT) Designation Downstream Industry Situation and Trend Overview

# CHAPTER 11 BREAKTHROUGH THERAPY (BT) DESIGNATION MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of Breakthrough Therapy (BT) Designation by Major Manufacturers
- 11.2 Production Value of Breakthrough Therapy (BT) Designation by Major Manufacturers
- 11.3 Basic Information of Breakthrough Therapy (BT) Designation by Major Manufacturers
- 11.3.1 Headquarters Location and Established Time of Breakthrough Therapy (BT) Designation Major Manufacturer
- 11.3.2 Employees and Revenue Level of Breakthrough Therapy (BT) Designation Major Manufacturer
- 11.4 Market Competition News and Trend
  - 11.4.1 Merger, Consolidation or Acquisition News
  - 11.4.2 Investment or Disinvestment News
  - 11.4.3 New Product Development and Launch

### CHAPTER 12 BREAKTHROUGH THERAPY (BT) DESIGNATION MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 12.1 Roche
  - 12.1.1 Company profile
  - 12.1.2 Representative Breakthrough Therapy (BT) Designation Product
  - 12.1.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross



### Margin of Roche

- 12.2 Abbvie
  - 12.2.1 Company profile
  - 12.2.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.2.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Abbvie
- 12.3 Novartis International AG
  - 12.3.1 Company profile
  - 12.3.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.3.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Novartis International AG
- 12.4 Janssen
  - 12.4.1 Company profile
  - 12.4.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.4.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Janssen
- 12.5 BMS
  - 12.5.1 Company profile
  - 12.5.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.5.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of BMS
- 12.6 Eli Lilly
  - 12.6.1 Company profile
  - 12.6.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.6.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Eli Lilly
- 12.7 Gilead
  - 12.7.1 Company profile
  - 12.7.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.7.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Gilead
- 12.8 Sanofi
  - 12.8.1 Company profile
  - 12.8.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.8.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Sanofi
- 12.9 Regeneron
  - 12.9.1 Company profile
  - 12.9.2 Representative Breakthrough Therapy (BT) Designation Product



- 12.9.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Regeneron
- 12.10 Acadia
  - 12.10.1 Company profile
  - 12.10.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.10.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Acadia
- 12.11 Boehringer Ingelheim
  - 12.11.1 Company profile
  - 12.11.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.11.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
- 12.12 Amgen
  - 12.12.1 Company profile
  - 12.12.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.12.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Amgen
- 12.13 AstraZeneca
  - 12.13.1 Company profile
  - 12.13.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.13.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of AstraZeneca
- 12.14 GlaxoSmithKline
  - 12.14.1 Company profile
  - 12.14.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.14.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 12.15 Vertex
  - 12.15.1 Company profile
  - 12.15.2 Representative Breakthrough Therapy (BT) Designation Product
- 12.15.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Vertex
- 12.16 Alexion
- 12.17 Merck
- 12.18 Jazz Pharmaceuticals
- 12.19 Exelixis
- 12.20 Eisai
- 12.21 Takeda
- 12.22 Pfizer



# CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION

- 13.1 Industry Chain of Breakthrough Therapy (BT) Designation
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

# CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION

- 14.1 Cost Structure Analysis of Breakthrough Therapy (BT) Designation
- 14.2 Raw Materials Cost Analysis of Breakthrough Therapy (BT) Designation
- 14.3 Labor Cost Analysis of Breakthrough Therapy (BT) Designation
- 14.4 Manufacturing Expenses Analysis of Breakthrough Therapy (BT) Designation

#### **CHAPTER 15 REPORT CONCLUSION**

### **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

- 16.1 Methodology/Research Approach
  - 16.1.1 Research Programs/Design
  - 16.1.2 Market Size Estimation
- 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
  - 16.2.1 Secondary Sources
  - 16.2.2 Primary Sources
- 16.3 Reference



### I would like to order

Product name: Breakthrough Therapy (BT) Designation-Global Market Status and Trend Report

2013-2023

Product link: https://marketpublishers.com/r/B7A5FF21892MEN.html

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

### **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/B7A5FF21892MEN.html">https://marketpublishers.com/r/B7A5FF21892MEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



